We found CD28 CAR-T and 28BBz CAR-T cells displayed higher tumor lysis capacity than 4-1BBz CAR-T cells in vitro at an E:T ratio of 25:1(Supplemental Fig. 2F) and then selected CD28 CAR-T and 28BBz CAR-T cells for in vivo antitumor assays. The gene discussed is CD28; the disease is neoplasm.